| Document Date: 2015-03-30 15:27:53
Open Document File Size: 426,18 KBShare Result on Facebook
Company Clinical / AMD / Retina-Vitreous Associates Medical Group / Neurotech Pharmaceuticals Inc. / / Country United States / / Event FDA Phase / / Facility University of Southern California Keck School / / IndustryTerm healthcare system / biotechnology / therapies for chronic eye diseases / / MedicalCondition glaucoma / disease / macular degeneration / ocular diseases / retinal degeneration / active disease / related macular degeneration / chronic eye diseases / recurrent subfoveal choroidal neovascularization / blindness / uveitis / / MedicalTreatment gene therapy / incision / / Organization U.S. Food and Drug Administration / FDA / University of Southern California Keck School of Medicine / / Person David Boyer / Quinton Oswald / / Position Professor of Ophthalmology / study investigator / Chief Executive Officer / Senior Partner / / Product Investigational New Drug Application / Anti-VEGF injections / NT-503 / / Region Southern California / / Technology gene therapy / drug delivery / Cell Therapy / biotechnology / / URL www.neurotechusa.com / /
SocialTag |
Neurotech Announces FDA Acceptance of Investigational New Drug Application and Clinical Trial Initiation of Novel Therapy for Wet AMD Efficacy and Safety of Long-term, Continuous Anti-VEGF will be Assessed in Phase 2 Stu